These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34448414)

  • 61. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
    Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma.
    Geurtsen ML; Kors WA; Moll AC; Smits C
    Ophthalmic Genet; 2017; 38(1):74-78. PubMed ID: 27050825
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of teprotumumab in thyroid eye disease.
    Greenhill C
    Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374
    [No Abstract]   [Full Text] [Related]  

  • 64. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.
    Slentz DH; Smith TJ; Kim DS; Joseph SS
    JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090
    [No Abstract]   [Full Text] [Related]  

  • 65. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
    Douglas RS; Kossler AL; Abrams J; Briceño CA; Gay D; Harrison A; Lee M; Nguyen J; Joseph SS; Schlachter D; Tan J; Lynch J; Oliver L; Perry R; Ugradar S
    J Neuroophthalmol; 2022 Sep; 42(3):334-339. PubMed ID: 35421877
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Teprotumumab for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652
    [No Abstract]   [Full Text] [Related]  

  • 67. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.
    Gozdas HT; Karabay O
    Indian J Pharmacol; 2015; 47(1):121-2. PubMed ID: 25821325
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT; Winzelberg J; Chang KW
    Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Teprotumumab: The First Approved Biologic for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2021 Apr; 61(2):53-61. PubMed ID: 33743528
    [No Abstract]   [Full Text] [Related]  

  • 72. Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.
    Thamprajamchit S; Jariengprasert C; Rajatanavin R
    Endocr Pract; 2004; 10(5):432-7. PubMed ID: 15760792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ototoxicity associated with vinblastine.
    Moss PE; Hickman S; Harrison BR
    Ann Pharmacother; 1999 Apr; 33(4):423-5. PubMed ID: 10332533
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sudden bilateral sensorineural hearing loss following polysubstance narcotic overdose.
    Schweitzer VG; Darrat I; Stach BA; Gray E
    J Am Acad Audiol; 2011 Apr; 22(4):208-14. PubMed ID: 21586255
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Teprotumumab for thyroid eye disease: early response is not required for benefit.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS
    Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The knowns and unknowns of teprotumumab for thyroid eye disease.
    Bednarczuk T; Pearce SH
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):323-325. PubMed ID: 33865499
    [No Abstract]   [Full Text] [Related]  

  • 77. Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population.
    Diniz SB; Cohen LM; Roelofs KA; Rootman DB
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):583-591. PubMed ID: 33710036
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of teprotumumab in chronic, clinically active thyroid eye disease.
    Yu CY; Simmons BA; Pham CM; Shriver EM
    Eye (Lond); 2022 Jul; 36(7):1500-1501. PubMed ID: 34983925
    [No Abstract]   [Full Text] [Related]  

  • 79. Teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Dallalzadeh LO; Liu CY
    Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids?
    Campbell AA
    JAMA Ophthalmol; 2022 Apr; 140(4):335-336. PubMed ID: 35175298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.